Dr. Vivien Sheehan (Baylor College) using the Lorrca Oxygenscan as a biomarker for a gene-based approach for SCD treatment.

Lorrca is included in hematological research and clinical discussions presented at the EHA25-2020. https://ehaweb.org/congress/eha25/virtual/

RR Mechatronics organiseert op 19 juni 2020 in samenwerking met patientenverenigingen Oscar Nederland en SZB een interactief bezoek aan ons bedrijf.


The American Society Hematology (ASH) Conference is world’s most comprehensive hematology event of the year. Also this year RR Mechatronics will be present, visit us at booth 665.

At the ASH several Lorrca related papers will be presented:

The European Hematology Association (EHA) Congress is world’s most comprehensive European Hematology event of the year. The 2019 edition was the 24th EHA Annual Meeting and was organized at our backdoor in Amsterdam. More than 11,000 hematology professionals and hundreds of exhibitors were present. Exhibitors included pharmaceutical companies, medical suppliers, publishers, non-profit organizations, clinical diagnostic and research-based companies.

RR Mechatronics was present with a great booth providing information about the capabilities of the Lorrca and giving “live” Lorrca Oxygenscan demonstrations as well. Attendees from Pharma, Hospitals and Research institutions have visited our booth and have joined the demonstrations. …

RR Mechatronics was present with a great booth providing information about the capabilities of the Lorrca and giving “live” Lorrca Oxygenscan demonstrations as well. Attendees from Pharma, Hospitals and Research institutions has visited our booth and have joined the demonstrations. For most of these visitors the ability to measure specific parameters to characterize, measure and monitor Sickle Cell Disease (SCD) was a real eye- opener. They realized no other technology has the ability to do this. Therefore, high interest was generated to include the Lorrca in research or (pre)clinical studies.

The poster that was presented by our collaborator from the University Medical Center Utrecht has generated a lot of attention as well. In addition to the their recently published paper about the Lorrca Oxygenscan they have shown that the Lorrca Oxygenscan provides useful biomarkers of clinical severity and treatment response, and may be essential in monitoring novel SCD treatments as part of a clinical trial.

One of the absolute highlights was the special organized Lorrca diner on a boat trip through the Amsterdam canals. During this diner we’ve hosted a nice mix of key persons from Pharma and Biotech companies but also clinicians and researchers.

In general, the EHA Conference was very successful, resulting in numerous quality leads and follow-up appointments. We’re looking already forward to our presence at the 61st American Society of Hematology (ASH) Conference that will be held in Orlando, Florida in December 2019.


On the 19th of June we celebrate World Sickle Cell Awareness Day. This day we raise the public awareness about the sickle cell disease, sickle cell patients and treatment methods for the disease.
Sickle cell disease (SCD) is an inherited genetic abnormality of hemoglobin (the oxygen-carrying protein) in red blood cells.

Sickle Cell Disease

The signs and symptoms of SCD are caused by the sickling of red blood cells (RBC). When red blood cells sickle, become crescent, they break down prematurely which often results in anemia. Anemia causes shortness of breath, fatigue and delayed growth and development in children. The rapid breakdown of red blood cells can also cause yellowing of the eyes and skin, which are signs of jaundice.

Sickle cell patients experience a lot of pain. This is due to the sickled RBC getting stuck in the blood vessels and the damage they inflict on the organs. Additional deprivation of oxygen-rich blood and concomitant high blood pressure contribute to this damage of the lungs, kidneys, spleen, and brain and can lead to heart failure.

The Lorrca Oxygenscan

For sickle cell patients, treatment options today include managing pain, infections and reducing the frequency of vaso-occlusive crises. But because the disease manifests itself differently with each person, each patient requires a personal individual treatment plan.

Until now there is no method available to determine the severity of the disease or to measure and monitor the effect of a treatment for the individual SCD patient. With our development of the Lorrca Oxygenscan, we believe to have succeeded in doing so. The Lorrca Oxygenscan measures the ‘Point of Sickling’ (PoS) in RBC samples from SCD patients. This unique measurement directly reflects the status of the samples’ susceptibility to oxygen depletion. The PoS is typical for each patients’ RBC sample and can’t be determined by any other technology. It is a functional phenotypic assay to assess SCD.

Substantial patient measurements have been published and presented by our collaborators at different congresses last year. They have shown that the Lorrca Oxygenscan can fully characterize RBC deformability under a range of oxygen concentrations. Key measurements like the PoS were different between genotypes, and changed significantly with standard of care SCD treatments (Rab et al; 2019). Therefore, this might act as a useful biomarker of clinical severity and treatment response, being essential in monitoring existing and novel SCD treatments.

We are aware and motivated to act.


The Lorrca Team of RR Mechatronics

Last month, eleven laboratories took part in a round trip of standardized material to test and compare the Lorrca measurements.
Execution of the Osmoscan resulted in good corresponding measurements. It was also noted that there was no significant lot-to-lot variation of the reagent.
These EQC will be performed annually from now on.